FDA Commissioner Announces Drug Competition Action Plan to Help Lower Drug Prices

FDA Commissioner Scott Gottlieb, MD, has unveiled a new plan to facilitate increased competition in the prescription drug market through approval of more lower-cost, generic medications.
Jackie Syrop
June 22, 2017
The FDA is also going to be examining policy and programmatic changes to address the issues thwarting generic competition. Some may be actions the FDA can take by using their own authorities more forcefully, while other steps might involve collaboration with sister agencies.
The Action Plan unveiled by the FDA Commissioner will grow and be updated as initial elements are implemented. The agency intends to broaden access to safe and effective generic drugs that can improve access to medicines and help consumers lower healthcare costs, but will steadfastly maintain FDA’s gold standard for rigorous, science-based regulation, Gottlieb promised.
Even though the actions promised by Gottlieb don’t affect branded drug spending until much later in the drug’s lifespan, his plan could be a setback to companies such as Turing Pharmaceuticals and Valeant Pharmaceuticals that specialize in buying up older, off-patent drugs and dramatically raising the prices once they become de facto monopolies. Targeting such “gaming” of the system would be an initial step in the FDA’s efforts to address generic drug markets, Gottlieb implied, and could later involve the Federal Trade Commission.


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.